Dianthus therapeutics announces fda clearance to initiate phase 2 trial of dnth103 in multifocal motor neuropathy (mmn)
Top-line results from phase 2 momentum trial in multifocal motor neuropathy anticipated in 2h 2026 building a neuromuscular franchise with dnth103 following the initiation of the phase 2 magic trial in generalized myasthenia gravis (gmg) in 1q'24 and planned initiation of a phase 2 trial in chronic inflammatory demyelinating polyneuropathy (cidp) in 2h'24 recently disclosed head-to-head affinity and pd potency data reinforce dnth103 is a highly potent, potential best-in-class active c1s inhibitor designed for self-administration in a low-volume, subcutaneous autoinjector once every two weeks new york and waltham, mass., june 12, 2024 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced u.s. food and drug administration (fda) clearance of its phase 2 investigational new drug (ind) application for the momentum trial of dnth103 in patients with multifocal motor neuropathy (mmn).
DNTH Ratings Summary
DNTH Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission